Abstract: A method for making an emulsified antiperspirant product is provided. The product has a continuous phase with a water-immiscible liquid and a disperse aqueous phase with an antiperspirant active. The method steps include providing a water-immiscible liquid; providing a volatile aqueous solution with an antiperspirant active; combining the water-immiscible liquid and the aqueous solution to form an emulsion with a continuous phase including the water-immiscible liquid and a disperse phase including the aqueous solution; providing a structurant separate from the emulsion and adding it to the emulsion to form an emulsified antiperspirant composition. The emulsified antiperspirant composition is heated to a temperature between 60° C. and 110° C. from 15 minutes to less than 2 hours. The emulsified antiperspirant composition is transferred into one or more dispensing containers. The batch weight of the emulsified antiperspirant composition may be greater than 20 kg.

Abstract: A method for treatment of malignant cells includes administering to the malignant cells nanoparticles and etoposide. The nanoparticles are selected from the group consisting of single wall carbon nanotubes, silver nanoparticles, gold nanoparticles and combinations thereof.

Abstract: The present disclosure relates to medical devices which contain one or more polymeric regions that are at least partially biodisintegrable in bodily fluid. These devices may be implanted or inserted into a subject for treatment of various diseases, disorders and conditions. The present disclosure further provides methods of slowing and/or accelerating the dissolution of such medical devices by administering a composition which alters the pH of the subject's urine.

Abstract: The invention features mucoadhesive sublingual films containing a pH neutralizing agent and apomorphine particles containing an acid addition salt of apomorphine. The pH neutralizing agent in these films can be sodium phosphate monobasic, sodium phosphate dibasic, sodium phosphate tribasic, potassium phosphate monobasic, potassium phosphate dibasic, potassium phosphate tribasic, or a mixture thereof.

Abstract: Disclosed are sublingual formulations of apomorphine in unit dosage form formulated for sublingual administration, where the unit dosage form is a mucoadhesive film containing a pH neutralizing agent and apomorphine particles containing an acid addition salt of apomorphine, and where the mucoadhesive film is formed by the steps of: (i) combining a film-forming mucoadhesive polymer, apomorphine particles comprising an acid addition salt of apomorphine, and a solvent to form a mixture; and (ii) pouring the mixture onto a surface and evaporating some of the solvent to form a first film comprising the apomorphine particles, where the steps further include contacting or impregnating the first film or mixture with a pH neutralizing agent to produce the mucoadhesive film containing the apomorphine particles and the pH neutralizing agent.

Abstract: Disclosed are methods of preparing a pharmaceutical composition that is a mucoadhesive film by: (i) combining a film-forming mucoadhesive polymer, apomorphine particles containing an acid addition salt of apomorphine, and a solvent to form a mixture; and (ii) pouring the mixture onto a surface and evaporating some of the solvent to form an intermediate film including the apomorphine particles; where the method further includes contacting or impregnating the intermediate film or mixture with a pH neutralizing agent to produce the mucoadhesive film containing the apomorphine particles and the pH neutralizing agent.

Abstract: Disclosed are methods of treating Parkinson's disease by (i) providing a pharmaceutical composition in unit dosage form that is a film having a first portion including apomorphine particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent, where the film contains the acid addition salt of apomorphine in an amount effective to treat Parkinson's disease, and (ii) administering the film by placing the film sublingually in the mouth of the subject and contacting sublingual mucosal tissue with the film.

Abstract: The invention relates to a pharmaceutical dosage form which comprises a solid dispersion product comprising N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or a salt, hydrate or solvate thereof, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer. The invention is further directed to processes for preparing the pharmaceutical dosage form and to use of the dosage form for treating proliferative disorders.

Abstract: Dehydroascorbic acid and polymeric/monomeric derivatives and isomers thereof are useful for artificially coloring the skin and more particularly as a skin self-tanning agent; the dehydroascorbic acid may be formed “in situ” from ascorbic acid or a derivative or salt thereof via chemical oxidation and/or via enzymatic oxidation, and a two-component agent thereof includes a) a first component (B) containing, in a physiologically acceptable medium, at least ascorbic acid or a derivative or salt thereof; b) a second component (C) containing, in a physiologically acceptable medium, at least one chemical oxidizing agent and/or one enzymatic oxidizing agent; components (B) and (C) being stored separately.

Abstract: Suspension concentrate compositions are disclosed for delivering S-(+)-Abscisic acid either alone or in combination with a second plant growth regulator to crop seed prior to planting as well as for foliar, soil drench, in-furrow and sprench (foliar spray and soil drench) applications are disclosed. The compositions, when properly combined in an aqueous carrier and processed through wet milling to achieve the desired particle size, will result in stable compositions that are desirable for treating crop seeds.

Abstract: The present invention relates to an antioxidant composition comprising a combination of galatomannan and N-acetyl cysteine for its use in the treatment of a skin disease or condition resulting from reactive oxygen species production in the skin or involving reactive oxygen species production in the skin, to a hydrogel containing said combination as well as to dressing wounds comprising said hydrogel and its use in the healing of ulcers, wounds, burns and scalds.

Abstract: A composition for delivering an active agent to a patient. The composition includes a polymer core encapsulating the active agent and a mucoadhesive coating disposed about the core. The polymer may include covalently linked poly(ethylene glycol) chains, and the mucoadhesive coating may be selected to facilitate transfer of the particle through the intestinal mucosa. A molecular weight and cross-link density of the polymer may be selected such that the polymer core will decompose in a predetermined time interval. The fraction of the dose of the drug entering the system at circulation during the predetermined time interval may be between about 0.25% and about 25%. The composition may be formulated as a plurality of nanoparticles or microparticles that are combined with a pharmaceutically acceptable carrier to produce an edible or inhalable drug product.

Abstract: Naturally occurring lecithins and/or oleic acid stimulate the growth and lactic acid producing activity of Lactobacillus and Bifidobacterium species of probiotic bacteria, and replace polysorbate 80 for those products. They can be used in naturally occurring form, or where they are to be combined with probiotics in a carrier, or they can be treated to yield a stable powdered form of these naturally oily compounds. They can be sold as combined prebiotic/probiotic formulations in the same carrier, or sold as separate dietary supplements, e.g., in capsule or tablet form, to be used with the probiotic formulation as desired.

Abstract: Described herein are compositions for manufacturing enteric soft capsules comprising gelatin, methyacrylic copolymers, one or more plasticizers, an alkaline aqueous solvent and, optionally, other ingredients such as colors, and flavors. Capsules made from such compositions are useful for delivery of acid-sensitive dosage forms to the lower gastrointestinal tract or to provide delayed release of active pharmaceutical ingredients.

Abstract: The present invention relates to a process for the preparation of a solid, orally administrable pharmaceutical composition, comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide in hydrophilized form, and its use for the prophylaxis and/or treatment of diseases.

Abstract: A process for the preparation of a solid, orally administrable pharmaceutical composition, comprising 5-chloro-N-({(5)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide comprising preparing granules in hydrophilized form using fluidized bed granulation for moist granulation, adding additives, compressing to form a tablet, and coating the tablet.

Abstract: The present invention relates to sustained-release pellets containing tacrolimus as an active ingredient. The sustained-release pellets of the present invention have multiple layers of hydroxypropyl methylcellulose, and may control the release of drugs by specific contents of hydroxypropyl methylcellulose and Surelease™, thus rendering the dissolution rate thereof uniform and stable, and enabling the dissolution rate to be adjusted as desired. The entire process for preparing the pellets of the present invention is carried out in a single fluidized-bed granulator, and therefore the preparation process is simplified and the time required for preparation is shortened while obtaining sustained-release pellets having uniform particle size distribution and contents. The sustained-release pellets of the present invention may have medicinal effects that last up to 24 hours, and therefore may be administered just once a day, thus improving patient compliance.

Abstract: A composition comprising: at least one alkoxysilane having at least one solubilizing functional group and at least one amino substituent; at least one glycosaminoglycan chosen from hyaluronic acid; water; optionally, at least one auxiliary ingredient; and optionally, at least one volatile solvent.

Abstract: The invention features methods involving the use of sublingual film formulations of apomorphine for treating Parkinson's disease. The methods involve providing the sublingual film formulation and administering the sublingual film formulation sublingually in the mouth of a subject by contacting sublingual mucosal tissue with the film.

Abstract: The present invention relates to a composition, comprising a microorganism of species Penicillium bilaji and at least one compound (II) in a synergistically effective amount.